Dapoflit GM 10-2-500 Tablet combines Dapagliflozin 10mg, Glimepiride 2mg, and Metformin 500mg to provide a comprehensive triple-mechanism approach for the management of type-2 diabetes mellitus. This formulation is designed for patients who require enhanced glycemic control beyond dual therapy.
Dapagliflozin supports glucose elimination via renal pathways, Glimepiride stimulates insulin secretion from pancreatic beta cells, and Metformin improves insulin sensitivity while reducing hepatic glucose output. Together, they help maintain stable blood glucose levels throughout the day.
The increased Glimepiride strength makes this combination suitable for patients with higher insulin requirements while maintaining a balanced safety profile. It is widely prescribed by diabetologists and physicians for long-term metabolic control and improved patient compliance.
Adding Dapoflit GM 2-500 Tablet to your portfolio strengthens your diabetes and metabolic-care segment, creating strong opportunities in chronic therapy supply, hospital procurement, pharmacy distribution, export markets, and third-party manufacturing. Its high prescription demand ensures consistent commercial performance.